Home Companies Catalysts Deep Dives
Vyloy zolbetuximab APPROVED
Drug Profile
ModalityAntibody
RouteIV
Therapy AreaOncology
Launch2024-10-18
US LOE2036-12-01
Peak Sales Est$1500M
Formulations[{"id":"vyloy-iv","route":"IV","setting":"INFUSION_CENTER","frequency":"Q3W with chemo","is_primary"
Companies
ALPMY (ORIGINATOR)100%
Mechanism: CLDN18.2-targeting
Expert: First-in-class anti-claudin 18.2 antibody inducing ADCC and CDC.
Everyday: Targets a protein on stomach cancer cells to trigger immune attack.
Targets: ["CLDN18.2"]
Revenue History
PeriodRevenue ($M)
FY2024$81M
H1 FY2025$177M
Programs (2)
IndicationStageKey StudyRegional Status
CLDN18.2+ G/GEJ adenocarcinoma 1LAPPROVEDSPOTLIGHT/GLOW[{"stage":"APPROVED","region":"US","approval_date":"2024-10-18"}]
CLDN18.2+ pancreatic adenocarcinomaPHASE3SPOTLIGHT-PDAC—
Upcoming Catalysts (2)
Vyloy - Global Launch Trajectory 2026
Vyloy + Keytruda + Chemo - 1L Gastric - Ph3 - Updates (LUCERNA) 2027+
Notes
First-in-class CLDN18.2 antibody for gastric/GEJ cancer. Rapid launch. Expanding to pancreatic.
Data from Supabase · Updated 2026-03-24